Shanghai Junshi Biosciences Co FCF yield
What is the FCF yield of Shanghai Junshi Biosciences Co?
The FCF yield of Shanghai Junshi Biosciences Co., Ltd. is -6.56%
What is the definition of FCF yield?
Free cash flow yield (FCF yield) is a financial ratio that compares the free cash flow per share to the market value per share. The ratio is calculated by dividing free cash flow per share by the current share price.
ttm (trailing twelve months)
Free cash flow yield is a good measure of the company’s cash flow in respect to the company’s size. Larger companies tend to have a higher cash flow yield, but it’s not always the case. The higher the free cash flow yield, the more cash the company is generating that can be quickly accessed to satisfy its obligations. The lower the free cash flow yield, the more money investors are putting into the company with little result. The higher the ratio, the more attractive the investment is as it suggests that investors are paying less for each unit of free cash flow.
Free cash flow acts as an indicator of how capable a company is of repaying all of its obligations. It is a solid indicator of how financially stable a company is. It is calculated as:
Free cash flow yield = Free cash flow per share / market price per share
FCF yield of companies in the Health Care sector on OTC compared to Shanghai Junshi Biosciences Co
What does Shanghai Junshi Biosciences Co do?
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Companies with fcf yield similar to Shanghai Junshi Biosciences Co
- Cairn PLC has FCF yield of -6.59%
- Anixa Biosciences has FCF yield of -6.58%
- Augros Cosmetic Packaging SA has FCF yield of -6.58%
- SMT Scharf AG has FCF yield of -6.57%
- Proteomics International Laboratories Ltd has FCF yield of -6.57%
- Dafy has FCF yield of -6.56%
- Shanghai Junshi Biosciences Co has FCF yield of -6.56%
- Dream Finders Homes has FCF yield of -6.54%
- MC Mining has FCF yield of -6.54%
- Betmakers Technology Ltd has FCF yield of -6.54%
- Ping An Healthcare and Technology has FCF yield of -6.54%
- Shenzhen Neoway Technology Co has FCF yield of -6.54%
- MAAS has FCF yield of -6.53%